ROCKVILLE, Md. & ALAMEDA, Calif.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, and South San Francisco-based Atria Genetics, Inc., a privately held company, today announced they have signed a definitive agreement whereby Celera will acquire substantially all of the assets of Atria for approximately $33 million in cash. Atria has a line of human leukocyte antigen (HLA) testing products that are used for identifying potential donors in the matching process for bone marrow transplantation. The transaction is subject to customary closing conditions and is expected to close during the second quarter of Celera’s fiscal 2008.
